Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Rosiñol, Laura; Oriol, Albert; Ríos, Rafael; Sureda, Anna; Jesús Blanchard, María; Hernández, Miguel‐Teodoro; Martínez‐Martínez, R.; M. Moraleda, José; Jarque, Isidro; Bargay, Juan; Gironella, Mercedes; de Arriba, Felipe; Palomera, Luis; González‐Montes, Yolanda; Martí, Josep; Krsnik, Isabel; Arguiñano, José-María; E. González, María; Pilar González, Ana; Felipe Casado, Luis; López‐Anglada, Lucía; Paiva, Bruno; Mateos, María‐Victoria; F. San Miguel, Jesús; José Lahuerta, Juan; Bladé, Joan

doi:10.1182/blood.2019000241

Public

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Published in Blood • Sep 4, 2019

Authors:

Laura Rosiñol

Albert Oriol

Rafael Ríos

Abstract

Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles fo...

Subject

Lenalidomide

Induction therapy

Dexamethasone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!